Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the UK / NCT07285252
Enrolling by invitation Not applicable

Evaluating Non-Invasive Haptics During Extreme Exercise

NCT07285252 · tracked via the Priya Life Science UK tracker
Sponsor
SuperPatch Limited LLC
Phase
Not applicable
Started
2025-01-05
Last updated
2026-08-20

Condition(s) studied

VO2maxLactate ThresholdLactate

Investigational drug(s) / intervention(s)

Victory Patch with Haptic Vibrotactile Trigger TechnologySham patch

Victory Patch with Haptic Vibrotactile Trigger Technology: Active Patch with Haptic Vibrotactile Trigger Technology

Sham patch: Sham/Placebo Patch without Haptic Vibrotactile Trigger Technology

Study summary

This study aims to compare determinants of endurance performance between participants wearing an active patch with haptic vibrotactile trigger technology (VTT) versus a placebo patch without VTT among recreational to competitive runners over a 4-week training period.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18 years and over, that participate in recreational to competitive distance running (\>2 structured runs per week), that were able to complete maximal treadmill exercise safely and were able to attend three laboratory visits were invited to participate. Exclusion Criteria: * Adults with a contraindications to high-intensity treadmill exercise, cardiovascular, metabolic, or musculoskeletal conditions limiting participation, reported use of performance-enhancing drugs, pregnancy, known allergy to adhesives, or current use of neuromodulatory or haptic devices

Primary outcome measure(s)

  • Change in VO2 Max — 2-weeks and 4-weeks after baseline assessment
    Change in VO₂max (mL/kg-¹/min-¹, calculated as a 30-second rolling average)

Trial sites (1)

FacilityCityRegionStatus
The Altitude Centre London UK

More SuperPatch Limited LLC trials in the UK

Recovery and Early Sleep Tracking Using the SuperPatch REM Patch Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07285252 on ClinicalTrials.gov ↗ ← All trials in the UK